The implementation of novel cancer immunotherapies in the form of immune checkpoint blockers represents a major advancement in the treatment of cancer, and has renewed enthusiasm for identifying new ways to induce antitumor immune responses in patients. Despite the proven efficacy of neutralizing antibodies that target immune checkpoints in some refractory cancers, many patients do not experience therapeutic benefit, possibly owing to a lack of antitumor immune recognition, or to the presence of dominant immunosuppressive mechanisms in the tumor microenvironment (TME). Recent developments in this field have revealed that local radiotherapy (RT) can transform tumors into in situ vaccines, and may help to overcome some of the barriers to tumo...
Despite the rising evidence in favor of immunotherapy (IT), the treatment of oncological patients af...
Thesis (Ph.D.)--University of Rochester. School of Medicine & Dentistry. Dept. of Microbiology and I...
Since the approval of anti-CTLA4 therapy (ipilimumab) for late-stage melanoma in 2011, the developme...
The implementation of novel cancer immunotherapies in the form of immune checkpoint blockers represe...
The implementation of novel cancer immunotherapies in the form of immune checkpoint blockers represe...
Advances in immunotherapy have achieved remarkable clinical outcomes in tumors with low curability, ...
A malignant tumor consists of malignant cells as well as a wide array of normal host tissues includi...
The conventional use of radiotherapy is for local tumor control. Radiotherapy of the primary tumor c...
Radiation has long been the standard of care for many types of cancer. It is employed to locally era...
Radiotherapy (RT), the major anti-cancer modality for more than half of cancer patients after diagno...
Radiotherapy (RT) is currently used in more than 50% of cancer patients during the course of their d...
The tumor microenvironment (TME) is an evolutionally low-level and embryonically featured tissue com...
Over thirty years ago, Helen Stone and colleagues compared the effects of local tumor irradiation in...
Radiotherapy (RT) with ionizing irradiation is commonly used to locally attack tumors. It induces a ...
© 2020 Joseph Ikin SiaRadiation therapy (RT) has evolved over more than a century into a well-establ...
Despite the rising evidence in favor of immunotherapy (IT), the treatment of oncological patients af...
Thesis (Ph.D.)--University of Rochester. School of Medicine & Dentistry. Dept. of Microbiology and I...
Since the approval of anti-CTLA4 therapy (ipilimumab) for late-stage melanoma in 2011, the developme...
The implementation of novel cancer immunotherapies in the form of immune checkpoint blockers represe...
The implementation of novel cancer immunotherapies in the form of immune checkpoint blockers represe...
Advances in immunotherapy have achieved remarkable clinical outcomes in tumors with low curability, ...
A malignant tumor consists of malignant cells as well as a wide array of normal host tissues includi...
The conventional use of radiotherapy is for local tumor control. Radiotherapy of the primary tumor c...
Radiation has long been the standard of care for many types of cancer. It is employed to locally era...
Radiotherapy (RT), the major anti-cancer modality for more than half of cancer patients after diagno...
Radiotherapy (RT) is currently used in more than 50% of cancer patients during the course of their d...
The tumor microenvironment (TME) is an evolutionally low-level and embryonically featured tissue com...
Over thirty years ago, Helen Stone and colleagues compared the effects of local tumor irradiation in...
Radiotherapy (RT) with ionizing irradiation is commonly used to locally attack tumors. It induces a ...
© 2020 Joseph Ikin SiaRadiation therapy (RT) has evolved over more than a century into a well-establ...
Despite the rising evidence in favor of immunotherapy (IT), the treatment of oncological patients af...
Thesis (Ph.D.)--University of Rochester. School of Medicine & Dentistry. Dept. of Microbiology and I...
Since the approval of anti-CTLA4 therapy (ipilimumab) for late-stage melanoma in 2011, the developme...